When planning the 3rd Annual PEGS China event, we sent out surveys to the international biotech industry asking a very important question….Where is China’s biotech industry heading towards? What are the bottlenecks in China biotech industry and what hoops do they need to jump through? The answers came in from all corners, from local conglomerates and small start-ups in China, to large multi-nationals and biotechs globally, and they all shared one key insight – China is entering the biotech revolution.
No longer seen merely as a manufacturing base or biosimilar developers, companies in China are increasingly being perceived as competitors and potential partners in novel biotherapeutics development. Local conglomerates are setting up biotherapeutic arms; multi-nationals are localizing research and development; innovative returnees are starting up new biotech ventures; and universities are spinning off novel ideas and training future generations in the protein sciences. All these are making China a futile ground for the growth of novel biotherapeutics.
At CHI’s 3rd Annual PEGS China, our goal is to bring the latest in protein & antibody engineering to help enhance the scientific expertise and knowledge of the scientists, as well as to foster international collaboration among local and international companies and institutions.
We are currently inviting presentation proposals on the below topics. Deadline for submission is September 4, 2016.
Please click on the individual program pages for details.